VANCOUVER, BC--(Marketwired - April 26, 2016) - Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today announced that its Chairman and Chief Executive Officer, Doug Janzen, will present at the fifth annual Bloom Burton & Co. Healthcare Investor Conference on Monday May 2nd, 2016 at 3:00pm Eastern Standard Time at the Sheraton Centre Toronto Hotel in Toronto, Ontario.
About Aequus Pharmaceuticals
Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) is a rapidly growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus' sales and marketing efforts are based in Canada, targeting highly specialized therapeutic areas including neurology, ophthalmology and transplant. Aequus is developing a pipeline of products in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems. Aequus intends to commercialize its internal programs in Canada and to establish strategic partnerships to accelerate and maximize the potential of its product candidates worldwide. For further information, please visit www.aequuspharma.ca.
About the Bloom Burton & Co. Healthcare Investor Conference
The conference will host approximately 60 of Canada's premier publicly traded and venture-backed private companies together with the most promising pre-venture companies in the healthcare industry. The event will attract Canadian, U.S. and International investors who are interested in the latest developments in Canadian healthcare companies. Investors will have the opportunity to obtain corporate updates from presenting companies, and participate in 1-on-1 meeting system with company management.
Contact Information: